Osimertinib for EGFR-mutant lung cancer

preview_player
Показать описание
Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines the approval and reimbursement of osimertinib in patients with EGFR mutant non-small cell lung cancer, based on the results of the FLAURA study. (NCT02296125). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)
  1. VJOncology
  2. Speaker: Jarushka Naidoo
  3. Institution: Beaumont Hospital
  4. Event: Gathering Around Cancer 2020
  5. Event: VJVirtual
  6. Subject: Lung Cancer
Рекомендации по теме
Osimertinib for EGFR-mutant 0:00:55

Osimertinib for EGFR-mutant lung cancer

Case 2: Osimertinib 0:03:09

Case 2: Osimertinib in EGFR-Mutated Lung Cancer

Osimertinib + ipilimumab 0:02:21

Osimertinib + ipilimumab in EGFR-mutated NSCLC

Therapeutic strategies for 0:02:23

Therapeutic strategies for EGFR-mutated lung cancer

Osimertinib plus gefitinib 0:03:31

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer

Dr. Fidler Discusses 0:00:42

Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer

Osimertinib For Uncommon 0:03:30

Osimertinib For Uncommon EGFR Mutations in NSCLC

Osimertinib for EGFR 0:03:59

Osimertinib for EGFR T790M Resistance Mutations in NSCLC

EGFR-Mutant Lung Cancer: 0:02:18

EGFR-Mutant Lung Cancer: A Patient's Journey

Osimertinib in Advanced 0:03:02

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

Dr. Wakelee on 0:01:57

Dr. Wakelee on Benefits of Osimertinib in EGFR-Mutant NSCLC Treatment

Continued use of 0:02:06

Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancer

Investigating Osimertinib for 0:00:48

Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer

Resistance to Osimertinib 0:01:53

Resistance to Osimertinib in EGFR-Mutated NSCLC

Current treatment recommendations 0:01:25

Current treatment recommendations and future directions for EGFR-mutant NSCLC

Phase III Data 0:01:45

Phase III Data Support Frontline Osimertinib in EGFR-Mutant Lung Cancers

Emerging Data in 0:07:08

Emerging Data in EGFR-Mutant Lung Cancer

Comment: Front-line osimertinib 0:01:36

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...

Phase III MARIPOSA: 0:03:17

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

Treating With Osimertinib 0:04:04

Treating With Osimertinib in EGFR-Mutated NSCLC

Case 4: EGFR 0:05:24

Case 4: EGFR Mutation Analysis Post-Osimertinib

Amivantamab and lazertinib 0:02:03

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

Resistance to Osimertinib 0:01:53

Resistance to Osimertinib in EGFR-Mutated NSCLC

Sequencing With Osimertinib 0:02:50

Sequencing With Osimertinib in EGFR-Mutated NSCLC